AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DLB
  4. [Form 4] Dolby Laboratories, Inc. Insider Trading Activity

[Form 4] Dolby Laboratories, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Dolby Laboratories (NYSE:DLB) CEO Kevin Yeaman filed a Form 4 for transactions on 06/24/2025.

  • Exercised 25,000 options at $45.50.
  • Immediately sold the same 25,000 Class A shares at a weighted-average $74.02, generating 鈮�$1.85 million in gross proceeds.
  • Sale represents about 18 % of the shares held in his family trust.
  • Post-trade holdings: 114,725 Class A shares (trust), 127,735 unvested RSUs, and 135,615 unexercised options.

The trades were executed under a Rule 10b5-1 plan; no additional corporate events were disclosed.

Kevin Yeaman, CEO di Dolby Laboratories (NYSE:DLB), ha presentato un modulo Form 4 relativo a operazioni effettuate il 24/06/2025.

  • Ha esercitato 25.000 opzioni al prezzo di 45,50 $.
  • Ha venduto immediatamente le stesse 25.000 azioni di Classe A a un prezzo medio ponderato di 74,02 $, generando circa 1,85 milioni di dollari di ricavi lordi.
  • La vendita rappresenta circa il 18% delle azioni detenute nel suo trust familiare.
  • Dopo l鈥檕perazione, detiene: 114.725 azioni di Classe A (trust), 127.735 RSU non ancora maturate e 135.615 opzioni non esercitate.

Le operazioni sono state eseguite nell鈥檃mbito di un piano Rule 10b5-1; non sono stati comunicati ulteriori eventi societari.

Kevin Yeaman, CEO de Dolby Laboratories (NYSE:DLB), present贸 un Formulario 4 por transacciones realizadas el 24/06/2025.

  • 贰箩别谤肠颈贸 25,000 opciones a $45.50.
  • Vendi贸 inmediatamente las mismas 25,000 acciones Clase A a un precio promedio ponderado de $74.02, generando aproximadamente $1.85 millones en ingresos brutos.
  • La venta representa cerca del 18 % de las acciones que posee en su fideicomiso familiar.
  • Despu茅s de la transacci贸n, posee: 114,725 acciones Clase A (fideicomiso), 127,735 RSU no adquiridas y 135,615 opciones no ejercidas.

Las operaciones se realizaron bajo un plan Rule 10b5-1; no se divulgaron eventos corporativos adicionales.

Dolby Laboratories (NYSE:DLB)鞚� CEO 旒�牍� 鞓堨澊毵�(Kevin Yeaman)鞚� 2025雲� 6鞗� 24鞚� 瓯半灅鞐� 雽�頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟.

  • 25,000欤� 鞓奠厴鞚� 欤茧嫻 45.50雼煬鞐� 頄夓偓頄堨姷雼堧嫟.
  • 歃夓嫓 霃欖澕頃� 25,000欤� 韥措灅鞀� A 欤检嫕鞚� 臧�欷戫弶攴� 74.02雼煬鞐� 毵る弰頃橃棳 鞎� 185毵� 雼煬鞚� 齑� 靾橃澋鞚� 鞓牳鞀惦媹雼�.
  • 鞚措矆 毵る弰電� 臧�臁� 鞁犿儊鞐� 氤挫湢 欷戩澑 欤检嫕鞚� 鞎� 18%鞐� 頃措嫻頃╇媹雼�.
  • 瓯半灅 頉� 氤挫湢 欤检嫕: 114,725欤� 韥措灅鞀� A (鞁犿儊), 127,735欤� 氙疙檿鞝� RSU, 135,615欤� 氙疙枆靷� 鞓奠厴.

瓯半灅电� Rule 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞙茧┌, 於旉皜 旮办梾 鞚措菠韸鸽姅 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Kevin Yeaman, PDG de Dolby Laboratories (NYSE:DLB), a d茅pos茅 un formulaire 4 relatif 脿 des transactions effectu茅es le 24/06/2025.

  • Il a exerc茅 25 000 options au prix de 45,50 $.
  • Il a imm茅diatement vendu les m锚mes 25 000 actions de Classe A 脿 un prix moyen pond茅r茅 de 74,02 $, g茅n茅rant environ 1,85 million de dollars de produit brut.
  • Cette vente repr茅sente environ 18 % des actions d茅tenues dans son trust familial.
  • Apr猫s la transaction, il d茅tient : 114 725 actions de Classe A (trust), 127 735 RSU non acquises et 135 615 options non exerc茅es.

Les transactions ont 茅t茅 effectu茅es dans le cadre d鈥檜n plan Rule 10b5-1 ; aucun autre 茅v茅nement d鈥檈ntreprise n鈥檃 茅t茅 divulgu茅.

Kevin Yeaman, CEO von Dolby Laboratories (NYSE:DLB), reichte ein Formular 4 f眉r Transaktionen am 24.06.2025 ein.

  • Er 眉bte 25.000 Optionen zu je 45,50 $ aus.
  • Verkaufte anschlie脽end sofort die zu einem gewichteten Durchschnittspreis von 74,02 $ und erzielte damit Bruttoerl枚se von ca. 1,85 Millionen $.
  • Der Verkauf entspricht etwa 18 % der im Familientrust gehaltenen Aktien.
  • Nach der Transaktion h盲lt er: 114.725 Class A Aktien (Trust), 127.735 nicht ausge眉bte RSUs und 135.615 nicht ausge眉bte Optionen.

Die Transaktionen wurden im Rahmen eines Rule 10b5-1 Plans durchgef眉hrt; weitere Unternehmensereignisse wurden nicht bekannt gegeben.

Positive
  • None.
Negative
  • CEO Kevin Yeaman sold 25,000 shares (鈮�$1.85 M), cutting his trust鈥檚 stake by ~18 %, a material insider disposition that may signal reduced near-term confidence.

Insights

CEO鈥檚 $1.85 M sale viewed as modestly bearish signal.

The exercise-and-sale combo lowers indirect holdings by ~18 % while monetising in-the-money options. Although governed by a 10b5-1 plan, reducing net exposure of 25 K shares may be interpreted as diminished short-term confidence. Yeaman still retains sizable equity through RSUs and options, tempering governance risk, but the cash-out exceeds the $1 M materiality bar, prompting a negative market read-through.

Planned insider sale limits legal risk; optics still negative.

The Rule 10b5-1 structure mitigates information-timing concerns, and the CEO鈥檚 remaining equity maintains incentive alignment. However, an 18 % stake reduction by the top executive can pressure sentiment and raise questions on valuation comfort. Absent concurrent insider buying or strategic disclosures, investors may treat the filing as a mild negative indicator rather than a governance red flag.

Kevin Yeaman, CEO di Dolby Laboratories (NYSE:DLB), ha presentato un modulo Form 4 relativo a operazioni effettuate il 24/06/2025.

  • Ha esercitato 25.000 opzioni al prezzo di 45,50 $.
  • Ha venduto immediatamente le stesse 25.000 azioni di Classe A a un prezzo medio ponderato di 74,02 $, generando circa 1,85 milioni di dollari di ricavi lordi.
  • La vendita rappresenta circa il 18% delle azioni detenute nel suo trust familiare.
  • Dopo l鈥檕perazione, detiene: 114.725 azioni di Classe A (trust), 127.735 RSU non ancora maturate e 135.615 opzioni non esercitate.

Le operazioni sono state eseguite nell鈥檃mbito di un piano Rule 10b5-1; non sono stati comunicati ulteriori eventi societari.

Kevin Yeaman, CEO de Dolby Laboratories (NYSE:DLB), present贸 un Formulario 4 por transacciones realizadas el 24/06/2025.

  • 贰箩别谤肠颈贸 25,000 opciones a $45.50.
  • Vendi贸 inmediatamente las mismas 25,000 acciones Clase A a un precio promedio ponderado de $74.02, generando aproximadamente $1.85 millones en ingresos brutos.
  • La venta representa cerca del 18 % de las acciones que posee en su fideicomiso familiar.
  • Despu茅s de la transacci贸n, posee: 114,725 acciones Clase A (fideicomiso), 127,735 RSU no adquiridas y 135,615 opciones no ejercidas.

Las operaciones se realizaron bajo un plan Rule 10b5-1; no se divulgaron eventos corporativos adicionales.

Dolby Laboratories (NYSE:DLB)鞚� CEO 旒�牍� 鞓堨澊毵�(Kevin Yeaman)鞚� 2025雲� 6鞗� 24鞚� 瓯半灅鞐� 雽�頃� Form 4毳� 鞝滌稖頄堨姷雼堧嫟.

  • 25,000欤� 鞓奠厴鞚� 欤茧嫻 45.50雼煬鞐� 頄夓偓頄堨姷雼堧嫟.
  • 歃夓嫓 霃欖澕頃� 25,000欤� 韥措灅鞀� A 欤检嫕鞚� 臧�欷戫弶攴� 74.02雼煬鞐� 毵る弰頃橃棳 鞎� 185毵� 雼煬鞚� 齑� 靾橃澋鞚� 鞓牳鞀惦媹雼�.
  • 鞚措矆 毵る弰電� 臧�臁� 鞁犿儊鞐� 氤挫湢 欷戩澑 欤检嫕鞚� 鞎� 18%鞐� 頃措嫻頃╇媹雼�.
  • 瓯半灅 頉� 氤挫湢 欤检嫕: 114,725欤� 韥措灅鞀� A (鞁犿儊), 127,735欤� 氙疙檿鞝� RSU, 135,615欤� 氙疙枆靷� 鞓奠厴.

瓯半灅电� Rule 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞙茧┌, 於旉皜 旮办梾 鞚措菠韸鸽姅 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Kevin Yeaman, PDG de Dolby Laboratories (NYSE:DLB), a d茅pos茅 un formulaire 4 relatif 脿 des transactions effectu茅es le 24/06/2025.

  • Il a exerc茅 25 000 options au prix de 45,50 $.
  • Il a imm茅diatement vendu les m锚mes 25 000 actions de Classe A 脿 un prix moyen pond茅r茅 de 74,02 $, g茅n茅rant environ 1,85 million de dollars de produit brut.
  • Cette vente repr茅sente environ 18 % des actions d茅tenues dans son trust familial.
  • Apr猫s la transaction, il d茅tient : 114 725 actions de Classe A (trust), 127 735 RSU non acquises et 135 615 options non exerc茅es.

Les transactions ont 茅t茅 effectu茅es dans le cadre d鈥檜n plan Rule 10b5-1 ; aucun autre 茅v茅nement d鈥檈ntreprise n鈥檃 茅t茅 divulgu茅.

Kevin Yeaman, CEO von Dolby Laboratories (NYSE:DLB), reichte ein Formular 4 f眉r Transaktionen am 24.06.2025 ein.

  • Er 眉bte 25.000 Optionen zu je 45,50 $ aus.
  • Verkaufte anschlie脽end sofort die zu einem gewichteten Durchschnittspreis von 74,02 $ und erzielte damit Bruttoerl枚se von ca. 1,85 Millionen $.
  • Der Verkauf entspricht etwa 18 % der im Familientrust gehaltenen Aktien.
  • Nach der Transaktion h盲lt er: 114.725 Class A Aktien (Trust), 127.735 nicht ausge眉bte RSUs und 135.615 nicht ausge眉bte Optionen.

Die Transaktionen wurden im Rahmen eines Rule 10b5-1 Plans durchgef眉hrt; weitere Unternehmensereignisse wurden nicht bekannt gegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
YEAMAN KEVIN J
(Last) (First) (Middle)
C/O DOLBY LABORATORIES, INC.
1275 MARKET STREET
(Street)
SAN FRANCISCO CA 94103
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Dolby Laboratories, Inc. [ DLB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/24/2025 M 25,000 A $45.5 139,725 I By a trust(1)
Class A Common Stock 06/24/2025 S 25,000 D $74.0212(2) 114,725 I By a trust(1)
Class A Common Stock 127,735(3) D
Class A Common Stock 2.5592 I By a son
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $45.5 06/24/2025 M 25,000 (4) 12/15/2026 Class A Common Stock 25,000 $0 135,615 I By a trust(1)
Explanation of Responses:
1. By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009
2. The shares were sold in multiple transactions at prices ranging from $73.34 to $74.33, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. Shares held following the reported transactions include 127,735 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.
4. This option was granted for a total of 194,399 shares of Class A Common Stock. The option exercised in this transaction was fully vested and exercisable as of the transaction date.
/s/ Daniel Rodriguez as Attorney-in-Fact for Kevin Yeaman 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Dolby (DLB) shares did CEO Kevin Yeaman sell on 24 June 2025?

He sold 25,000 Class A shares as reported in the Form 4.

What was the total dollar value of the shares sold by DLB's CEO?

The weighted-average sale price was $74.02, valuing the sale at approximately $1.85 million.

Did Kevin Yeaman increase or decrease his ownership in Dolby?

Ownership decreased; the trust鈥檚 holdings fell from 139,725 to 114,725 shares after the sale.

Was the CEO's transaction executed under a 10b5-1 trading plan?

Yes. The Form 4 indicates the sale was made pursuant to a Rule 10b5-1 plan.

How many unexercised options does the CEO hold after this filing?

He retains 135,615 unexercised employee stock options.
Stock DLB logo
Dolby Laboratories Inc

NYSE:DLB

DLB Rankings

#1438 Ranked by Market Cap
#1499 Ranked by Dividends

DLB Latest News

Jun 24, 2025
Dolby and Audi announce partnership to integrate Dolby Atmos
Jun 23, 2025
Dolby, Lenovo, and Google Unveil the World's First Chromebook with Dolby Atmos
May 27, 2025
TCL Brings Dolby Atmos FlexConnect to 2025 QD-Mini LED TVs
May 12, 2025
Dolby Laboratories President and CEO Kevin Yeaman to Host Fireside Chat at the William Blair 45th Annual Growth Stock Conference
May 1, 2025
Dolby Laboratories Reports Second Quarter 2025 Financial Results

DLB Latest SEC Filings

Jun 24, 2025
[144] Dolby Laboratories, Inc. SEC Filing

DLB Stock Data

7.13B
60.53M
1.37%
93.4%
0.62%
Specialty Business Services
Patent Owners & Lessors
United States
SAN FRANCISCO